Mid-cap Health Care company Jazz Pharmaceuticals has logged a -8.0% change today on a trading volume of 1,515,934. The average volume for the stock is 568,645.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company is now trading -36.8% away from its average analyst target price of $188.83 per share. The 18 analysts following the stock have set target prices ranging from $135.0 to $235.0, and on average give Jazz Pharmaceuticals a rating of buy.
Over the last 12 months JAZZ shares have declined by -10.1%, which represents a difference of -37.5% when compared to the S&P 500. The stock's 52 week high is $147.98 per share and its 52 week low is $111.25. With its net margins declining an average -33.3% over the last 6 years, Jazz Pharmaceuticals declining profitability gives us reason to believe its stock price will continue to underwhelm.
Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
---|---|---|---|---|
2023 | 3,794,392 | 79,954 | 2 | 133.33 |
2022 | 3,659,374 | -224,060 | -6 | 45.45 |
2021 | 3,094,238 | -329,668 | -11 | -210.0 |
2020 | 2,363,567 | 238,616 | 10 | -58.33 |
2019 | 2,161,761 | 523,367 | 24 | 0.0 |
2018 | 1,890,922 | 447,098 | 24 | n/a |